Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for process/pmg6 returned no results
Showing 931 to 945 of 2854 results for process

  1. Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6457]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 21 May 2026.

  2. Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 22 May 2026.

  3. Giredestrant with everolimus for treating oestrogen-receptor positive HER2-negative advanced breast cancer after cyclin-dependent kinase 4 and 6 inhibitor and endocrine treatment [ID6576]

    Awaiting development Reference number: GID-TA11773 Expected publication date:  27 May 2027

  4. 12 SQ-HDM SLIT for treating allergic rhinitis caused by house dust mites in children 5 to 11 years [ID6510]

    In development Reference number: GID-TA11635 Expected publication date:  26 August 2026

  5. Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment [ID3753]

    In development Reference number: GID-TA10620 Expected publication date:  12 June 2026

  6. Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]

    In development Reference number: GID-TA11519 Expected publication date: TBC

  7. Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]

    In development Reference number: GID-TA11819 Expected publication date:  03 September 2026

  8. DCVax-L for treating glioblastoma [ID836]

    In development Reference number: GID-TA10143 Expected publication date: TBC

  9. How to apply to join a committee

    guidance that improves services. Applying is easy. Follow our step-by-step process to get started. Get involved NICE Implementation...

  10. How to apply to join a committee

    guidance that improves services. Applying is easy. Follow our step-by-step process to get started. Get involved NICE Implementation...

  11. Intraoperative blood cell salvage in obstetrics (HTG90)

    Evidence-based recommendations on intraoperative blood cell salvage in obstetrics. This involves filtering and washing shed blood and retransfusing it during or after the procedure.

  12. Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence (CG76)

    This guideline covers medicines adherence in people aged 18 and over. It recommends how to encourage adherence to medicines by supporting and involving people in decisions about their prescribed medicines. It aims to ensure that a person’s decision to use a medicine is an informed choice.

  13. Linerixibat for treating pruritus in people with primary biliary cholangitis [ID6265]

    Awaiting development Reference number: GID-TA11307 Expected publication date:  06 January 2027

  14. Care of dying adults in the last days of life (NG31)

    This guideline covers the clinical care of adults (18 years and over) who are dying during the last 2 to 3 days of life. It aims to improve end of life care for people in their last days of life by communicating respectfully and involving them, and the people important to them, in decisions and by maintaining their comfort and dignity. The guideline covers how to manage common symptoms without causing unacceptable side effects and maintain hydration in the last days of life.

  15. Mental wellbeing and independence for older people (QS137)

    This quality standard covers interventions to maintain and improve the mental wellbeing and independence of people aged 65 or older, and how to identify those at risk of a decline. It describes high-quality care in priority areas for improvement. It does not cover the mental wellbeing and independence of people who live in a care home or attend one on a day-only basis.